New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy

STOCKHOLM, Oct. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB today announced that its commercial partner Everest Medicines received approval from the Pharmaceutical Administration Bureau...

Related Keywords

China ,Stockholm ,Sweden ,Macau , ,Nasdaq Stockholm ,Everest Medicines ,Pharmaceutical Administration Bureau ,Macau Special Administrative Region ,Priority Review ,Breakthrough Therapy Designation ,Shanghai Ruijin Hospital ,Markets ,